



What's New

04.01.2017

Ceiling Price fixation of Coronary Stents.

Department of Pharmaceuticals (DoP) has notified Coronary Stents as part of Schedule-1 of DPCO, 2013 vide S.O. 4100(E) dated 21.12.2016. Accordingly, NPPA has initiated the exercise of determination of ceiling price of Coronary Stents.

But NPPA is not in a position, as of now, to calculate and upload draft 'provisional price' as per DoP letter no. 31015/44/2016-PI.I dated 11.7.2016 as like other scheduled drugs, the market data of PTR is not being captured by AIOCD (Pharmatrac) because of the different nature of trade channels in case of Coronary Stents where hospitals/nursing homes are acting as de-facto 'Retailers'.

However, inspite of these limitations, in the interest of widest Stakeholders' consultation, following options of price control is likely to be put up to Authority which, however, may consider any other options within the ambit of DPCO, 2013:-

- (a) Average of Price to Distributes (PTD)/Price to Stockiest (PTS) + 16% Retailer Margin, if applicable.
- (b) CGHS prices +10% increase per annum as applicable in case of nonscheduled drugs under para 20.
- (c) Cos of production (CoP) + 35% Trade Margin for Domestic manufactured Stents as suggested by Sub- Committee report on Trade Margin.
- (d) Landed Cost (LC) + 35% Trade Margin for Imported Stents as suggested by Sub-Committee report on Trade Margin.
- (e) Average of (CGHS + PTD/PTS) + 16% Retailer Margin. If applicable.
- (f) Any other Methodology suggested by Stakeholders.

Any Stakeholder may make representation with authenticated data/information within 10 working days to NPPA in order to make necessary action in the matter.

["Ceiling Price fixation of Coronary Stents\(updated as on 04.01.2017\)."](#)